
Reminder: This page provides global information for HCP or scientific research audience that may not be applicable in your country.
Locally approved resources can be found here.
The general public, dealers and retailers are informed that the National Pharmaceutical Pricing Authority, Government of India, has capped the trade margin on non-scheduled anti-cancer medicines by Order S.O. 5690(E) dated 17 October 2026. In compliance with the Order, Astellas Pharma India Private Limited has reduced the Maximum Retail Price (MRP) of XTANDI® (Enzalutamide Capsules 40 mg), pack of 112 capsules, from Rs 3,14,657.82 to Rs 1,04,885.94, inclusive of GST, with effect from 9 November 2026.
From 9 November 2026, XTANDI® shall not be sold in India above the revised MRP, even if a higher MRP is printed on the pack. Patients and caregivers may contact the Company at AID_Finance@astellas.com or phone number: 022-61557600